DUPIXENT (Sanofi-Aventis Australia Pty Ltd)
Dupixent is indicated for the following type 2 inflammatory diseases:
Atopic Dermatitis
Adults and adolescents
Dupixent is indicated for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.
Children 6 to 11 years of age
Dupixent is indicated for the treatment of severe atopic dermatitis in patients aged 6 to 11 years old who are candidates for chronic systemic therapy. Dupixent is not intended for episodic use.
Prurigo Nodularis
Dupixent is indicated for the treatment of moderate-to-severe prurigo nodularis (PN) in adults who are candidates for systemic therapy.
Asthma
Dupixent is indicated as add on maintenance treatment in patients aged 6 years and older with moderate to severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO) that is inadequately controlled despite therapy with other medicinal products for maintenance treatment (see Section 5.1 Pharmacodynamic Properties – Clinical Trials).
Chronic rhinosinusitis with nasal polyposis (CRSwNP)
Dupixent is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).